Beta Bionics, Inc. (BBNX)
NASDAQ: BBNX · Real-Time Price · USD
22.46
-0.08 (-0.33%)
Feb 11, 2025, 2:17 PM EST - Market open
Beta Bionics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Revenue | 53.03 | 12 | 0.18 |
| Revenue Growth (YoY) | - | 6601.12% | - |
| Cost of Revenue | 23.77 | 5.69 | - |
| Gross Profit | 29.26 | 6.31 | 0.18 |
| Selling, General & Admin | 48.41 | 24.22 | 33.5 |
| Research & Development | 21.43 | 17.94 | 31.43 |
| Operating Expenses | 69.84 | 42.16 | 64.92 |
| Operating Income | -40.58 | -35.85 | -64.74 |
| Interest Expense | -0.06 | -0.07 | -0.01 |
| Interest & Investment Income | 4.21 | 1.78 | 0.2 |
| Other Non Operating Income (Expenses) | -19.07 | -9.96 | 0.91 |
| EBT Excluding Unusual Items | -55.5 | -44.1 | -63.65 |
| Other Unusual Items | - | - | -1.1 |
| Pretax Income | -55.5 | -44.1 | -64.75 |
| Net Income | -55.5 | -44.1 | -64.75 |
| Net Income to Common | -55.5 | -44.1 | -64.75 |
| Shares Outstanding (Basic) | 11 | 10 | 10 |
| Shares Outstanding (Diluted) | 11 | 10 | 10 |
| Shares Change (YoY) | - | 6.13% | - |
| EPS (Basic) | -4.89 | -4.22 | -6.58 |
| EPS (Diluted) | -4.89 | -4.22 | -6.58 |
| Free Cash Flow | -43.49 | -32.85 | -60.98 |
| Free Cash Flow Per Share | -3.83 | -3.14 | -6.19 |
| Gross Margin | 55.17% | 52.59% | 100.00% |
| Operating Margin | -76.52% | -298.87% | -36169.83% |
| Profit Margin | -104.64% | -367.64% | -36173.74% |
| Free Cash Flow Margin | -82.00% | -273.84% | -34067.04% |
| EBITDA | -39.37 | -34.62 | -63.4 |
| EBITDA Margin | -74.24% | -288.65% | - |
| D&A For EBITDA | 1.21 | 1.23 | 1.35 |
| EBIT | -40.58 | -35.85 | -64.74 |
| EBIT Margin | -76.52% | -298.87% | - |
| Revenue as Reported | 12 | 12 | 0.18 |
Source: S&P Capital IQ. Standard template.
Financial Sources.